| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/21/2001 | CN1062176C Oral liquid for curing cancer |
| 02/21/2001 | CN1062138C RNA from poultry embryo and its medical use |
| 02/20/2001 | US6191304 Vitronectin receptor antagonists |
| 02/20/2001 | US6191282 Derivatives of 5-membered nitrogen containing heterocyclic ring is used as anticarcinogenic agent and anticoagulant |
| 02/20/2001 | US6191271 Synthetic divalent sLex containing polylactosamines and methods for use |
| 02/20/2001 | US6191266 Sugar modified nucleosides |
| 02/20/2001 | US6191261 Immunoglobulin that preferential binds a growth factor; for the diagnosis and treatment of cell proliferative defects; antiproliferative agents |
| 02/20/2001 | US6191172 Used in drugs and cosmetics |
| 02/20/2001 | US6191148 Omerazole process and compositions thereof |
| 02/20/2001 | US6191147 Pyrazole compounds and uses thereof |
| 02/20/2001 | US6191123 Organic-arsenic compounds |
| 02/20/2001 | US6190909 TH2-specific gene |
| 02/20/2001 | US6190887 Expression of an exogenous gene in a mammalian cell by use of a non-mammalian DNA virus having an altered coat protein |
| 02/20/2001 | US6190875 Method of screening for potential anti-metastatic and anti-inflammatory agents using mammalian heparanase as a probe |
| 02/20/2001 | US6190869 Antisense inhibition of protein kinase C-theta expression |
| 02/20/2001 | US6190693 Administering pharmaceutical formulation comprising hormonal replacememt for treating or preventing menopausal condition and folic acid |
| 02/20/2001 | US6190657 Vectors for the diagnosis and treatment of solid tumors including melanoma |
| 02/20/2001 | US6190641 Indocyanine dyes |
| 02/20/2001 | US6190640 Administering indium radiolabelled humanized monoclonal antibody or a in radiolabelled binding fragment of a humanized monoclonal antibody which binds to antigen a33 which is presented on surfaces of cells of cancer carcinoma |
| 02/20/2001 | CA2302629C Estrogen receptor |
| 02/20/2001 | CA2192289C Substituted heterocyclic derivatives |
| 02/20/2001 | CA2191789C Biaromatic compounds containing an adamantyl group in ortho position; pharmaceutical and cosmetic compositions containing them and use thereof |
| 02/20/2001 | CA2122519C Cancer treatment and metastasis prevention |
| 02/20/2001 | CA2049341C Regional chemotherapy with 4-hydroperoxycyclophosphamide |
| 02/20/2001 | CA2043536C Tumor cell growth inhibitor |
| 02/20/2001 | CA1341182C Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof |
| 02/15/2001 | WO2001011369A1 Cancer treatments and diagnostics utilizing rad51 related molecules and methods |
| 02/15/2001 | WO2001011089A1 Novel method for screening compound for preventing or treating liver cell injury caused by hepatitis c virus and compound obtained by this method |
| 02/15/2001 | WO2001011067A1 Genetically altered dendritic cells transduced with adeno-associated virus (aav), methods of producing said cells and uses thereof |
| 02/15/2001 | WO2001011063A2 Gene transfer combination vectors, method for the production and utilization thereof |
| 02/15/2001 | WO2001011059A1 Fv antibody construct comprising binding sites for a cd16 receptor and a cd30 surface protein |
| 02/15/2001 | WO2001011050A1 Fhm, A NOVEL MEMBER OF THE TNF LIGAND SUPERGENE FAMILY |
| 02/15/2001 | WO2001011046A1 Dendritic enriched secreted lymphocyte activation molecule |
| 02/15/2001 | WO2001011044A1 Tumor antigen |
| 02/15/2001 | WO2001011040A1 Tumor-associated antigen (r11) |
| 02/15/2001 | WO2001011038A2 Medicament for the prevention and/or the treatment of ischemic heart and peripheral vascular diseases, tumour and wounds |
| 02/15/2001 | WO2001011027A1 New protein |
| 02/15/2001 | WO2001011024A2 Bryostatins, bryopyrans and polyketides: compositions and methods |
| 02/15/2001 | WO2001011023A1 Treatment of inflammatory or malignant disease using dnazymes |
| 02/15/2001 | WO2001010913A1 Potentiation of inclusion complex formation of cyclodextrin derivatives |
| 02/15/2001 | WO2001010912A1 Multiple cytokine-antibody complexes |
| 02/15/2001 | WO2001010902A2 Nucleoc acids and secreted polypeptides encoded thereby |
| 02/15/2001 | WO2001010877A1 C-glycoside analogs and methods for their preparation and use |
| 02/15/2001 | WO2001010859A1 Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity |
| 02/15/2001 | WO2001010857A1 Compounds having antitumor, antiviral and antibacterial activities |
| 02/15/2001 | WO2001010847A2 Novel integrin receptor antagonists |
| 02/15/2001 | WO2001010842A2 Melanocortin-4 receptor binding compounds and methods of use thereof |
| 02/15/2001 | WO2001010841A2 Fluorene derivatives as integrin inhibitors |
| 02/15/2001 | WO2001010829A1 Novel vitamin d analogues |
| 02/15/2001 | WO2001010827A1 Arylsulfonamido-substituted hydroxamic acid derivatives |
| 02/15/2001 | WO2001010468A2 Drug-carrier complexes and methods of use thereof |
| 02/15/2001 | WO2001010462A1 Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies |
| 02/15/2001 | WO2001010461A1 New clinical parameters for determining hematologic toxicity prior to radioimmunotherapy |
| 02/15/2001 | WO2001010460A1 Treatment of intermediate- and high-grade non-hodgkins lymphoma with anti-cd20 antibody |
| 02/15/2001 | WO2001010457A2 Pharmaceutical compositions containing tripeptides |
| 02/15/2001 | WO2001010446A2 Formulations for parenteral use of estramustine phosphate and albumin |
| 02/15/2001 | WO2001010440A1 COMPOSITIONS AND METHODS TO ENHANCE CANCER CHEMOTHERAPY IN p53 DEFECTIVE TUMORS |
| 02/15/2001 | WO2001010427A2 Use of anti-muscarinic agents for treating skin disorders |
| 02/15/2001 | WO2001010426A2 Use of ep4 receptor ligands in the treatment of neuropathic pain and colon cancer |
| 02/15/2001 | WO2001010423A2 Use of 5-ht3 receptor antagonists for the treatment of inflammations of the respiratory tract |
| 02/15/2001 | WO2001010421A1 Drug releasing biodegradable fiber implant |
| 02/15/2001 | WO2001010416A1 Method of delivering a chemotherapeutic agent to a solid tumor |
| 02/15/2001 | WO2001010411A2 Implantable active ingredient depot |
| 02/15/2001 | WO2001010383A2 Caspase inhibitors and uses thereof |
| 02/15/2001 | WO2001010382A2 Compositions and methods related to claudin-7 |
| 02/15/2001 | WO2001010381A2 Methods for treating or preventing pain and anxiety |
| 02/15/2001 | WO2001010380A2 Benzanilides as potassium channel openers |
| 02/15/2001 | WO2001010199A1 A knockout mouse for the tumor suppressor gene anx7 |
| 02/15/2001 | WO2000069884A3 Compositions isolated from skin cells and methods for their use |
| 02/15/2001 | WO2000068385A3 Novel nucleic acids and proteins with growth hormone activity |
| 02/15/2001 | WO2000068384A3 NOVEL NUCLEIC ACIDS AND PROTEINS WITH p53 ACTIVITY AND ALTERED TETRAMERIZATION DOMAINS |
| 02/15/2001 | WO2000066584B1 1-AMINO TRIAZOLO¢4,3-a! QUINAZOLINE-5-ONES AND OR -5-THIONES INHIBITING PHOSPHODIESTERASE IV |
| 02/15/2001 | WO2000065054A3 Human membrane-associated proteins |
| 02/15/2001 | WO2000064946A3 Compositions and methods for cancer treatment by selectively inhibiting vegf |
| 02/15/2001 | WO2000064874A3 Heterosubstituted pyridine derivatives as pde 4 inhibitors |
| 02/15/2001 | WO2000061184A3 Dry formulation for transcutaneous immunization |
| 02/15/2001 | WO2000059513A8 NON-CALCEMIC, ANTIPROLIFERATIVE, TRANSCRIPTIONALLY ACTIVE SULFUR-CONTAINING ANALOGS OF 1α, 25-DIHYDROXY VITAMIN D¿3? |
| 02/15/2001 | WO2000059483A3 Transdermal drug delivery devices comprising a polyurethane drug reservoir |
| 02/15/2001 | WO2000057920A3 Method for expressing proteins |
| 02/15/2001 | WO2000057852A3 Methods and compositions for treating solid tumors |
| 02/15/2001 | WO2000052165A3 Compositions and methods for breast cancer therapy and diagnosis |
| 02/15/2001 | WO2000049144A3 Pyk2 binding proteins |
| 02/15/2001 | WO2000044908A3 Comp/tsp-1, comp/tsp-2 and other tsp chimeric proteins |
| 02/15/2001 | WO1999042102A8 Indole-3-propionic acids, salts and esters thereof used as medicaments |
| 02/15/2001 | DE19937656A1 Verwendung von Antithrombin III zur Prophylaxe und Therapie von Erkrankungen The use of antithrombin III for the prophylaxis and treatment of diseases |
| 02/15/2001 | DE19937264A1 F¶v¶-Antikörper-Konstrukte F¶v¶ antibody constructs |
| 02/15/2001 | DE19936997A1 Verfahren zur Nutzung von Dendrimeren als Multiplikatoren zur Verabreichung von Photosensibilisatoren Procedures for the use of dendrimers as multipliers for administration of photosensitizers |
| 02/15/2001 | DE19936780A1 Neue Antagonisten von Integrinrezeptoren New antagonists of integrin |
| 02/15/2001 | CA2383230A1 Tumor-associated antigen (r11) |
| 02/15/2001 | CA2382659A1 Dendritic enriched secreted lymphocyte activation molecule |
| 02/15/2001 | CA2381910A1 Novel vitamin d analogues |
| 02/15/2001 | CA2381846A1 Potentiation of inclusion complex formation of cyclodextrin derivatives |
| 02/15/2001 | CA2381621A1 Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity |
| 02/15/2001 | CA2381396A1 Polynucleotides and polypeptides encoded thereby |
| 02/15/2001 | CA2381293A1 Genetically altered dendritic cells transduced with adeno-associated virus (aav), methods of producing said cells and uses thereof |
| 02/15/2001 | CA2381290A1 Bryostatins, bryopyrans and polyketides: compositions and methods |
| 02/15/2001 | CA2381284A1 Fhm, a novel member of the tnf ligand supergene family |
| 02/15/2001 | CA2381008A1 Melanocortin-4 receptor binding compounds and methods of use thereof |
| 02/15/2001 | CA2380981A1 Fluorene derivatives |
| 02/15/2001 | CA2380678A1 Treatment of inflammatory or malignant disease using dnazymes |